Danish pharmaceutical giant Novo Nordisk is gearing up to introduce its blockbuster anti-diabetes and weight-loss drug Wegovy (semaglutide) in India. In a strategic move to gain an advantage over Eli Lilly’s newly launched Mounjaro (tirzepatide), Novo Nordisk has presented data showcasing Wegovy’s cardiovascular benefits in Indian patients, according to recent regulatory filings.
Emergency Response: Extra Flights Deployed After Pahalgam Terror Attack
Following the tragic terrorist attack in Kashmir's Pahalgam that claimed at least 28 lives on Tuesday, Indian airlines have announced additional flight operations to assist with urgent travel needs. On Wednesday, both...
Discussion about this post